-
Something wrong with this record ?
Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres
R. Jorda, K. Paruch, V. Krystof,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Cyclin-Dependent Kinases antagonists & inhibitors MeSH
- Heterocyclic Compounds chemistry pharmacology MeSH
- Protein Kinase Inhibitors chemistry pharmacology MeSH
- Humans MeSH
- Neoplasms drug therapy enzymology MeSH
- Antineoplastic Agents chemistry pharmacology MeSH
- Purines chemistry pharmacology MeSH
- Drug Design MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clinical trials as a candidate drug for some oncological indications. Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies. This article reviews known roscovitine bioisosteres that have been prepared as CDK inhibitors using different core heterocycles. The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochemical activity - only six direct analogs containing different purine bioisosteres have been prepared and evaluated side by side with roscovitine. Only four types of bioisosteres have demonstrated improved biological properties, namely pyrazolo[ 1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13000829
- 003
- CZ-PrNML
- 005
- 20130109113159.0
- 007
- ta
- 008
- 130108s2012 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/138161212800672804 $2 doi
- 035 __
- $a (PubMed)22571665
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Jorda, Radek $u Laboratory of Growth Regulators, Palacky University, Slechtitelu 11, 78371, Olomouc, Czech Republic.
- 245 10
- $a Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres / $c R. Jorda, K. Paruch, V. Krystof,
- 520 9_
- $a Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clinical trials as a candidate drug for some oncological indications. Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies. This article reviews known roscovitine bioisosteres that have been prepared as CDK inhibitors using different core heterocycles. The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochemical activity - only six direct analogs containing different purine bioisosteres have been prepared and evaluated side by side with roscovitine. Only four types of bioisosteres have demonstrated improved biological properties, namely pyrazolo[ 1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a cyklin-dependentní kinasy $x antagonisté a inhibitory $7 D018844
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a heterocyklické sloučeniny $x chemie $x farmakologie $7 D006571
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory $x farmakoterapie $x enzymologie $7 D009369
- 650 _2
- $a inhibitory proteinkinas $x chemie $x farmakologie $7 D047428
- 650 _2
- $a puriny $x chemie $x farmakologie $7 D011687
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Paruch, Kamil
- 700 1_
- $a Krystof, Vladimír
- 773 0_
- $w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 18, č. 20 (2012), s. 2974-80
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22571665 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130108 $b ABA008
- 991 __
- $a 20130109113304 $b ABA008
- 999 __
- $a ok $b bmc $g 963611 $s 798993
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 18 $c 20 $d 2974-80 $i 1873-4286 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
- LZP __
- $a Pubmed-20130108